GLP-1 Medicines in India Now Cheaper

India's patent on semaglutide, a key molecule in several well-known weight management and diabetes medicines, expired on 20 March 2026. This led to the introduction of cheaper versions of these medicines within days. The price drop is a significant gain for a country like India, which has one of the world's largest burdens of metabolic disease.

The treatment, which previously cost tens of thousands of rupees per month, now starts at around a thousand rupees at the lower end. Dozens of manufacturers have entered the category since the patent expired. GLP-1 receptor agonists work by mimicking a hormone released by the gut after eating, slowing stomach emptying and reducing appetite.

However, doctors emphasize that the price drop does not mean that anyone can start taking these medicines. Suitability is a clinical decision that requires a doctor's assessment of a patient's medical history, existing conditions, and other medicines. The dose is stepped up gradually, rather than started at full strength.

According to Dr Ratnil Joshi, a consultant physician in internal medicine at Karespot, GLP-1 medicines are not for everyone. They are only suitable for people whose specialist recommends them after a proper assessment. Weight is now treated as a medical condition because appetite and fullness are regulated by hormones, rather than resolve. Factors like sleep, stress, thyroid function, certain medications, and genetics all play a role in how the body stores weight.

The World Health Organization frames obesity as a chronic, relapsing disease arising from interactions between genetics, neurobiology, eating behavior, diet, and environment. This framing matters, as people who view their weight as a personal failing are less likely to seek medical help. In contrast, those who understand it as a disease are more likely to seek help earlier.

Supervised care for weight management involves more than just a prescription. The World Health Organization recommends that these medicines be used alongside healthy diets, physical activity, and support from health professionals. Behavioral therapy may also be offered to people taking these medicines. The recommendation is conditional, citing limited long-term evidence on what happens after treatment stops.

Programs like Karespot are working to provide supervised care and support to people taking GLP-1 medicines. This involves watching for the body's response to the treatment and providing guidance on healthy diets and physical activity. By moving the work of keeping people on treatment into the home, these programs aim to improve outcomes and support people in their weight management journey.

In conclusion, the price drop of GLP-1 medicines in India is a significant development, but it is only one part of the story. The real gain is in providing access to a treatment with strong evidence behind it, but it is crucial to ensure that this treatment is used responsibly and under medical supervision. As India continues to grapple with the burden of metabolic disease, it is essential to prioritize supervised care and support for people taking these medicines.